Dindot Receives Inaugural Chancellor’s Innovation Award
Dr. Scott Dindot, an associate professor in the Texas A&M School of Veterinary Medicine & Biomedical Sciences’ Department of Veterinary Pathobiology and in the School of Medicine’s Department of Molecular & Cellular Medicine, was named the inaugural Chancellor’s Innovation Award recipient at The Texas A&M University System Innovation Luncheon on April 14. The Chancellor’s Innovation […]
Texas A&M Researchers Detail Groundbreaking Angelman Syndrome Development
A new publication explains the novel science behind the first molecular therapeutic for the rare neurogenetic disorder to advance into clinical development. Researchers at Texas A&M University have developed the first molecular therapeutic for Angelman syndrome to advance into clinical development. In a new article, published today in Science Translational Medicine, Dr. Scott Dindot, an […]
Biopharmaceutical Company Expands Clinical Trials For Texas A&M-Developed Angelman Syndrome Treatment
A treatment for a rare disease that was researched and developed in the laboratory of Texas A&M School of Veterinary Medicine & Biomedical Sciences (VMBS) associate professor Scott Dindot has not only produced encouraging interim data from a phase 1/2 clinical trial in the United States, United Kingdom, and Canada but has become the subject […]
CVM’s Dindot Recognized With 2019 Innovation Award
Dr. Scott V. Dindot, an associate professor in the College of Veterinary Medicine & Biomedical Sciences’ (CVM) Department of Veterinary Pathobiology (VTPB), is one of three faculty members from across the Texas A&M campus to be recognized with a 2019 Innovation Award. The award, presented during the Texas A&M Technology Commercialization’s (TTC) annual Patent and […]
A&M Research Receives FDA Orphan-Drug Designation for Angelman Syndrome Treatment
College Station, Texas — The U.S. Food and Drug Administration has granted orphan-drug designation to GTX-101 for the treatment of Angelman syndrome, a rare neurogenetic disorder that affects approximately 1 in 15,000 people. GTX-101 is the first drug candidate for startup GeneTx Biotherapeutics, LLC (GeneTx). “No approved treatments for Angelman syndrome exist today,” said Allyson […]
Angelman Syndrome Treatment Being Investigated
Research from the laboratory of Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVM) associate professor Scott Dindot has become the basis for an investigational antisense drug that researchers hope will lead to the treatment of Angelman syndrome (AS). Investigational-new-drug-enabling studies on the potential therapeutic are currently underway with GeneTx Biotherapeutics LLC (GeneTx), a […]
